TDMS Study 56111-04 Pathology Tables
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
Final#1/Mice
Facility: Battelle Columbus Laboratory
Chemical CAS #: 14371-10-9
Lock Date: 06/28/00
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50 50
Early Deaths
Natural Death 5 6 9 5 3
Moribund Sacrifice 2 3 4 1 4
Survivors
Terminal Sacrifice 42 41 36 44 43
Natural Death 1 1
Animals Examined Microscopically 50 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (50) (50) (50) (50) (50)
Intestine Large, Colon (50) (50) (50) (50) (50)
Intestine Large, Rectum (50) (50) (50) (50) (50)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Intestine Large, Cecum (50) (50) (50) (49) (50)
Intestine Small, Duodenum (50) (49) (50) (50) (50)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (50) (50) (50) (50) (50)
Carcinoma 1 (2%)
Liver (50) (49) (50) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma 1 (2%) 2 (4%)
Hepatocellular Adenoma 4 (8%) 3 (6%) 4 (8%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%)
Mesentery (3) (4) (5) (4) (1)
Carcinoma, Metastatic, Uterus 1 (25%)
Fibrosarcoma 1 (33%)
Hemangioma 1 (33%)
Histiocytic Sarcoma 1 (20%) 1 (25%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (33%)
Pancreas (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (48) (50) (48) (49) (50)
Stomach, Forestomach (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Page 2
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%) 3 (6%)
Tooth (2) (1) (1)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (49) (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50) (50)
Subcapsular, Adenoma 1 (2%)
Adrenal Medulla (49) (50) (50) (50) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Pituitary Gland (48) (49) (50) (49) (50)
Pars Distalis, Adenoma 5 (10%) 6 (12%) 1 (2%) 4 (8%) 2 (4%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (48) (50) (49) (50) (50)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (49) (50) (49) (50)
Carcinoma 1 (2%)
Ovary (50) (50) (50) (49) (50)
Cystadenoma 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Granulosa Cell Tumor Benign 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Luteoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Thecoma Benign 1 (2%)
Page 3
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Oviduct (1) (1) (2) (3) (4)
Histiocytic Sarcoma 1 (33%)
Uterus (50) (50) (50) (50) (50)
Carcinoma 1 (2%)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50) (50)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node (7) (5) (7) (10) (7)
Lumbar, Histiocytic Sarcoma 1 (10%)
Mediastinal, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (14%)
Mediastinal, Carcinoma, Metastatic, Uterus 1 (10%)
Pancreatic, Histiocytic Sarcoma 1 (10%)
Pancreatic, Osteosarcoma, Metastatic,
Uncertain Primary Site 1 (14%)
Pancreatic, Rhabdomyosarcoma, Metastatic,
Skeletal Muscle 1 (14%)
Lymph Node, Mandibular (46) (47) (45) (49) (47)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node, Mesenteric (49) (49) (50) (49) (50)
Carcinoma, Metastatic, Clitoral Gland 1 (2%)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%)
Spleen (48) (49) (50) (50) (50)
Hemangiosarcoma 2 (4%) 1 (2%)
Thymus (46) (47) (46) (47) (47)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50) (50)
Adenoma 1 (2%)
Fibroadenoma 1 (2%)
Skin (50) (50) (50) (50) (50)
Squamous Cell Carcinoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 2 (4%) 2 (4%) 3 (6%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Schwannoma Malignant 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50) (50)
Vertebra, Osteosarcoma 1 (2%)
Skeletal Muscle (1)
Rhabdomyosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 2 (4%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Carcinoma, Metastatic, Clitoral Gland 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Carcinoma, Metastatic, Uterus 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (2%) 1 (2%)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Metastatic, Skin 1 (2%)
Nose (49) (50) (50) (50) (50)
Pleura (1)
Page 5
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (1) (4) (5)
Adenoma 1 (50%) 1 (100%) 3 (75%) 3 (60%)
Carcinoma 1 (50%) 1 (25%) 2 (40%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50) (50)
Carcinoma, Metastatic, Uterus 1 (2%)
Urinary Bladder (50) (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%)
Lymphoma Malignant 13 (26%) 10 (20%) 6 (12%) 8 (16%) 14 (28%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 32 29 21 24 21
Total Primary Neoplasms 43 41 28 36 27
Total Animals with Benign Neoplasms 17 15 10 14 7
Total Benign Neoplasms 18 18 15 16 9
Total Animals with Malignant Neoplasms 23 22 12 16 16
Total Malignant Neoplasms 25 23 13 20 18
Total Animals with Metastatic Neoplasms 3 3 3 2
Total Metastatic Neoplasm 6 4 7 7
Total Animals with Malignant Neoplasms 1 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50 50
Early Deaths
Natural Death 6 3 4 9
Moribund Sacrifice 2 1
Survivors
Terminal Sacrifice 43 45 46 39 49
Natural Death 1 2
Animals Examined Microscopically 50 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (50) (50) (50) (50)
Intestine Large, Cecum (50) (50) (50) (50) (50)
Intestine Small, Duodenum (50) (50) (50) (50) (49)
Polyp Adenomatous 1 (2%) 1 (2%)
Intestine Small, Jejunum (50) (50) (50) (50) (50)
Carcinoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Liver (50) (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 6 (12%) 7 (14%) 7 (14%) 4 (8%) 3 (6%)
Hepatocellular Adenoma 5 (10%) 7 (14%) 5 (10%) 5 (10%) 4 (8%)
Hepatocellular Adenoma, Multiple 2 (4%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Mesentery (2) (1)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (100%)
Oral Mucosa (1)
Pharyngeal, Squamous Cell Papilloma 1 (100%)
Pancreas (50) (50) (50) (50) (50)
Hemangioma 1 (2%)
Salivary Glands (50) (50) (50) (49) (50)
Stomach, Forestomach (48) (50) (50) (48) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%)
Stomach, Glandular (50) (50) (50) (50) (50)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (49) (50) (50) (49) (50)
Subcapsular, Adenoma 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Pituitary Gland (48) (50) (49) (50) (49)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (49) (50) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Preputial Gland (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%)
Prostate (50) (50) (50) (50) (50)
Seminal Vesicle (50) (50) (50) (50) (50)
Testes (50) (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymph Node (3) (2) (2) (3) (2)
Lumbar, Histiocytic Sarcoma 1 (50%)
Page 9
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mediastinal, Histiocytic Sarcoma 1 (50%) 1 (33%)
Mediastinal, Squamous Cell Carcinoma,
Metastatic, Stomach, Forestomach 1 (33%)
Renal, Fibrous Histiocytoma 1 (50%)
Renal, Histiocytic Sarcoma 1 (50%)
Lymph Node, Mandibular (49) (49) (49) (46) (48)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mesenteric (48) (49) (46) (46) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Plasma Cell Tumor Malignant 1 (2%)
Spleen (50) (50) (50) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Thymus (44) (43) (44) (44) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangioma 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50) (50)
Rib, Fibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 2 (4%) 6 (12%) 7 (14%) 1 (2%) 7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 5 (10%) 1 (2%) 2 (4%) 6 (12%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 3 (6%) 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Nose (48) (48) (48) (48) (50)
Histiocytic Sarcoma 1 (2%)
Pleura (1) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (100%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (4) (4) (1) (3)
Adenoma 4 (100%) 4 (100%) 3 (75%) 1 (100%) 2 (67%)
Carcinoma 1 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50) (50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Urinary Bladder (50) (50) (50) (50) (50)
Squamous Cell Carcinoma, Metastatic, Stomach,
Forestomach 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant 4 (8%) 4 (8%) 1 (2%) 2 (4%) 2 (4%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 11
NTP Experiment-Test: 56111-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRANS-CINNAMALDEHYDE Date: 06/14/01
Route: DOSED FEED Time: 09:19:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD VEHICLE .312% .625% 1.25%
CONTROL CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 23 34 27 17 22
Total Primary Neoplasms 31 44 34 23 28
Total Animals with Benign Neoplasms 14 23 16 9 15
Total Benign Neoplasms 17 25 20 11 16
Total Animals with Malignant Neoplasms 12 16 14 11 12
Total Malignant Neoplasms 14 19 14 12 12
Total Animals with Metastatic Neoplasms 1 1 4 4
Total Metastatic Neoplasm 1 3 4 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------